Non-Small-Cell Lung Cancer

Osimertinib Is Still Standard First-Line Treatment for NSCLC With EGFR Mutation

10/13/2018

Osimertinib remains the standard approach for first line therapy in EGFR mutated NSCLC.

Osimertinib remains the standard...

10/13/2018

Oncology

Alectinib Maintains First-Line Therapy Status for ALK-Positive NSCLC

10/13/2018

For patients with NSCLC and ALK mutation, first-line therapy with alectinib is standard care, however, sequence of therapy is not so readily defined.

For patients with NSCLC and ALK...

10/13/2018

Oncology

Liquid Biopsies Improve Delivery of Targeted Therapy in Metastatic NSCLC

10/12/2018

Adding a liquid biopsy to standard care tumor surveillance led to a marked increase in the detection of mutations that can be targeted with therapy, a recent study has shown.

Adding a liquid biopsy to...

10/12/2018

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Non-Small-Cell Lung Cancer

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products